Dingdang Health Technology Group Ltd. released a Next Day Disclosure Return dated 6 July 2026 detailing its recent equity movements and on-market share repurchases.
Key disclosures
1. Share capital position • Issued shares (excluding treasury shares) stood at 1.25 billion as of both 3 July and 6 July 2026, indicating no new share issuances during the period. • The company held no treasury shares at either date.
2. Ongoing buy-back activity • Between 19 May and 6 July 2026, Dingdang Health repurchased 14.03 million ordinary shares earmarked for cancellation, equal to approximately 1.12 % of the current issued share base (1.25 billion shares). • The most recent transaction on 6 July 2026 involved 150,000 shares purchased on the Hong Kong Stock Exchange at HKD 0.94 each, for a total consideration of HKD 0.14 million. • Under the shareholder mandate granted on 23 June 2026, the company is authorised to repurchase up to 124.32 million shares; 2.55 million shares (0.21 % of issued shares at mandate date) have been bought back under this authority to date. • All repurchased shares are designated for cancellation; none are being held as treasury stock.
3. Regulatory compliance and restrictions • The board confirms that every repurchase complied with Hong Kong Main Board Listing Rule 10.06 and all other applicable regulations. • Owing to the 30-day moratorium following share buy-backs, Dingdang Health is restricted from issuing new shares or transferring treasury shares until 5 August 2026.
Overall, Dingdang Health’s latest filing highlights an active share repurchase programme with no change to its outstanding share capital as of 6 July 2026, while signalling continued capacity under its authorised buy-back mandate.
Comments